The Importance of Antiretroviral Drugs in the Treatment of HIV and Coronavirus Disease

Catherine Jeffreys

Department of Clinical Science and Education, Medical University of South Carolina, USA

Corresponding Author: Catherine Jeffreys
Department of Clinical Science and Education
Medical University of South Carolina, USA
E-mail: [email protected]

Submitted: September 02, 2021; Accepted: September 16, 2021; Published: September 23, 2021

Visit for more related articles at Quality in Primary Care


Individuals living with HIV who are not taking antiretroviral treatment (ART) and have a low CD4 cell count, especially those with cutting edge HIV sickness, are at expanded danger of pioneering diseases and AIDS related difficulties. Be that as it may, there is advancing and clashing proof whether individuals living with HIV have an expanded danger of securing of SARSCoV-2 disease or potentially COVID-19 clinical confusions in PLHIV contrasted with everyone.

PLHIV can have a more noteworthy pervasiveness of the realized danger factors for COVID-19 securing and entanglements, like coronary illness, kidney sickness, diabetes, constant pneumonic sickness, weight, just as, other comorbidities and co-diseases, similar to tuberculosis.

A few case report series and little associate examinations among hospitalized PLHIV with COVID-19 have shown equivalent clinical results and comparative danger of SARS CoV2 disease when contrasted and overall public, especially in those with very much controlled HIV contamination (on ART and with a CD4 count > 200 cells/mm3 and stifled viral burden). These restricted clinical information recommend the mortality hazard in PLHIV is related with referred to COVID-19 factors, for example, more seasoned age and presence of comorbidities including cardiovascular sickness, diabetes, ongoing respiratory infection and weight [1-3].

There have been a few deliberate and non-methodical audits that assessed COVID-19 results among PLHIV; most have found equivalent results of mortality and grimness when contrasted and HIV negative patients [4]. Methods didn't generally incorporate appraisal of results while controlling for known COVID-19 danger factors.

One methodical survey, eminently distributed as a pre-print, found of 144,795 hospitalized COVID-19 patients in North America, Europe, and Asia the pooled commonness of HIV in COVID-19 patients was 1.22% (95% (CI): 0.61%-2.43%)) meaning a 2-overlay increment contrasted with the particular neighborhood level pooled HIV predominance in everyone of 0.65% (95% CI: 0.48%-0.89%) which indicated a likely powerlessness among PLHIV.

Extra information on this subject come from a few companion examines from South Africa, the USA and the UK have detailed a moderate expanded danger of death straightforwardly credited to HIV disease after changes for age, sex, nationality and presence of comorbidities; an unpublished meta-investigation including these examinations tracked down that the danger of death was practically twofold that of HIV-negative patients; in any case, frustrating by comorbidities related with expanded danger of serious COVID-19 can't be precluded.

Securing individuals living with HIV during the COVID-19 pandemic, and guaranteeing they can keep up with treatment, is basic. Scientists are presently researching whether individuals with HIV have an expanded danger of poor results with COVID-19. Primer proof of moderate expanded weakness of individuals with HIV makes it considerably more critical that individuals with HIV approach ARVs and therapies for comorbidities – like therapy for hypertension, cardiovascular sickness, persistent pneumonic infection, diabetes, tuberculosis, and support of a sound body weight.

A bigger dataset from a more extensive topographical portrayal is needed to grow comprehension of what SARS-CoV-2 cocontamination with HIV means for the seriousness of ailment, infection movement and results from hospitalization with COVID-19. For this reason, WHO has set up a Global COVID-19 Clinical Platform. Starting at 4 November 2020, WHO has gotten clinical information from 79 000 patients hospitalized with affirmed or suspected COVID-19, including from 5. 291 hospitalized patients living with HIV, from more than 30 nations all throughout the planet. The stage is available to all Member States and wellbeing offices to contribute information and incorporation will assist with advising future direction on how best to guarantee PLHIV are very much secured during the COVID-19 pandemic [5,6].

PLHIV are encouraged to take a similar COVID-19 safeguards as suggested for everybody wash hands frequently; practice hack manners; guarantee physical removing; wear covers when proper and as per neighborhood guidelines; look for clinical consideration if indicative; hole up on the off chance that one creates side effects or has contact with a positive COVID-19 case; and different activities per the nearby and government reaction. Various little investigations have surveyed whether antiretrovirals can be utilized to keep disease from SARSCoV2, regularly with dissonant outcomes.

A new report recommends that individuals living with HIV who were utilizing tenofovir disoproxil fumarate (TDF) were less inclined to contract SARS-CoV-2. In any case, different examinations show that tenofovir-based HIV pre-openness prophylaxis (PrEP) doesn't give security against contamination the new Covid, nor does it improve the course of COVID-19 sickness. In this review, pervasiveness of SARS-CoV-2 was really higher among individuals taking PrEP contrasted with people who were not.

As is normal practice, experienced preexposure prophylaxis (PrEP) clients might be given multi-month remedies as indicated by public direction which might incorporate standard STI testing. People starting PrEP should keep on returning for a 1-month follow-up HIV testing and facility visit prior to getting multimonth solutions. This is to preclude intense HIV contamination, survey unfavorable impacts and decide expectation to proceed with PrEP use. In any case, adaptability for the 1-month visit can be considered for spurred customers who have not had a new (in the beyond 3 weeks) likely openness to HIV. These choices could be presented on a defense by-case premise among suppliers and customers starting PrEP interestingly. Telehealth and local area administering can be considered for follow up. Quality-guaranteed HIV self-testing can be considered for upkeep.


1. Zhu F, Cao Y, Xu S, Zhou M. Co infection of SARS CoV2 and HIV in a patient in Wuhan city China. J Med Virology 2020.

2. Guo W, Ming F, Dong Y. A Survey for COVID-19 among HIV/AIDS Patients in Two Districts of Wuhan, China. The Lancet 2020.

3. Gudipati S, Brar I, Murray S, McKinnon JE, Yared N. Descriptive Analysis of Patients Living with HIV Affected by COVID-19. J Acquir Immune Defic Syndr 2020;85:123- 126.

4. Mirzaei H, McFarland W, Karamouzian M. COVID-19 Among People Living with HIV: A Systematic Review. AIDS Behav 2020.

5. Boulle A, Davies MA, Hussey H. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020; 1198.

6. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS 2020; 34:F3-F8

Select your language of interest to view the total content in your interested language

Viewing options

Flyer image
journal indexing image

Share This Article

agar io

rolex replica

wormax io